Scientific presentations including slides, posters and abstracts
Lizama B, Duong D, Pandey K, et al. Plasma Proteomic Analysis from Alzheimer’s Patients in SPARC Clinical Trial to Identify Pharmacodynamic Biomarkers of the S2R Modulator CT1812. Poster presented at: AD/PD™ 2024 Alzheimer’s & Parkinson’s Diseases Conference; Lisbon, Portugal.
Di Caro V, Pandey K, Duong D, et al. Analysis of CSF Samples from a Phase 2 Clinical Trial in Alzheimer’s Patients Show that CT1812 can Modulate α-synuclein. Poster presented at: AD/PD™ 2024 Alzheimer’s & Parkinson’s Diseases Conference; Lisbon, Portugal.
Caldwell J, Cho E, Knezovich N, et al. A transcriptomic analysis to investigate the role of sigma-2 receptor modulators CT1812 and CT2168 in a mouse model of Alzheimer’s disease. Poster presented Nov 2023 at: Society for Neuroscience (SfN) annual meeting; Washington DC.
Cho E, Caldwell J, Pandey K, et al. A proteomic analysis to elucidate the role of sigma-2 receptor modulators CT1812 and CT2168 in a mouse model of Alzheimer’s disease. Poster presented Nov 2023 at: Society for Neuroscience (SfN) annual meeting; Washington DC.
Reaver AJ, Lizama BN, Pandey K, et al. Exploratory omics study reveals potential roles of sigma-2 receptor modulators in AAV1/2A53T-aSyn rat model of Parkinson’s disease. Poster presented Nov 2023 at: Society for Neuroscience (SfN) annual meeting; Washington DC.
Lizama BN, Reaver AJ, Pandey K, et al. Unbiased proteomic and transcriptomic analysis of Sigma-2 receptor modulation in an in vivo model of synucleinopathy. Poster presented Nov 2023 at: Society for Neuroscience (SfN) annual meeting; Washington DC.
Di Caro V, Pandey K, Lizama B, et al. Proteomic Analysis in a Phase 2 Clinical Trial Studying CT1812 to Identify CSF and Plasma Pharmacodynamic Biomarkers and Molecular Correlates of EEG in Alzheimer’s Patients. Poster presented Oct 2023 at: Clinical Trials on Alzheimer’s Disease (CTAD); Boston, Massachusetts.
Lizama B, Cho E, Duong D, et al. Proteomic Analysis of Plasma in a Phase 2 Clinical Trial in Alzheimer’s Patients to Identify Pharmacodynamic Biomarkers of the S2R Modulator CT1812. Poster presented Oct 2023 at: Clinical Trials on Alzheimer’s Disease (CTAD); Boston, Massachusetts.
Di Caro V, Cho E, Caldwell J, et al. Brain transcriptomic and proteomic analyses in an in vivo AD model further elucidate the role of the sigma-2 receptor modulator CT1812 in Alzheimer’s disease. Poster presented at: 2023 Alzheimer’s Association’s International Conference (AAIC); Amsterdam, The Netherlands.
Pandey K, Duong D, Waybright L, et al. Pharmacodynamic Effects of the S2R Modulator CT1812 in Alzheimer’s Disease (AD) Patients Observed in a Meta-analysis of CSF Proteomes from SPARC and SHINE Part A. Poster presented at: AD/PD™ 2023 International Conference on Alzheimer’s and Parkinson’s Diseases
Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.
Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.
Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.
Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.
Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.
